Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
accesso® Acquires Dexibit®, Establishing the First Cross Platform AI and Analytics Platform for Visitor Attractions PR Newswire - Mon Mar 30, 1:01AM CDT

Acquisition launches accesso Intelligence SM , connecting guest and operator data, insight and action across the entire operation

AIM : 0.5850 (+6.17%)
accesso® Acquires Dexibit®, Establishing the First Cross Platform AI and Analytics Platform for Visitor Attractions PR Newswire - Mon Mar 30, 1:01AM CDT

Acquisition launches accesso Intelligence SM , connecting guest and operator data, insight and action across the entire operation

AIM : 0.5850 (+6.17%)
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors GlobeNewswire - Wed Mar 18, 7:36AM CDT

OCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced that the Japan Patent Office has fully approved a Japanese...

AIM : 0.5850 (+6.17%)
AIM ImmunoTech Announces Closing of its Rights Offering GlobeNewswire - Fri Mar 6, 6:00PM CST

OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...

AIM : 0.5850 (+6.17%)
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million GlobeNewswire - Wed Mar 4, 8:00AM CST

OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...

AIM : 0.5850 (+6.17%)
AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer GlobeNewswire - Mon Mar 2, 8:00AM CST

OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM)  (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business...

AIM : 0.5850 (+6.17%)
AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering GlobeNewswire - Fri Feb 27, 8:00AM CST

OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...

AIM : 0.5850 (+6.17%)
AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026 GlobeNewswire - Wed Feb 25, 8:00AM CST

OCALA, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and...

AIM : 0.5850 (+6.17%)
The State Fair of Texas Extends Partnership with accesso® Through 2030, Embracing Innovation and Guest Convenience PR Newswire - Tue Feb 24, 7:00AM CST

ORLANDO, Fla. , Feb. 24, 2026 /CNW/ --  accesso Technology Group  (AIM: ACSO), the leading technology partner to the leisure and entertainment industry, today announced the renewal...

AIM : 0.5850 (+6.17%)
The State Fair of Texas Extends Partnership with accesso® Through 2030, Embracing Innovation and Guest Convenience PR Newswire - Tue Feb 24, 7:00AM CST

ORLANDO, Fla. , Feb. 24, 2026 /PRNewswire/ --  accesso Technology Group  (AIM: ACSO), the leading technology partner to the leisure and entertainment industry, today announced the renewal...

AIM : 0.5850 (+6.17%)

Barchart Exclusives

This Dividend King Is Down 26%. When Will It Bounce Back? Barchart - Tue Mar 31, 6:30PM CDT
Abbott Laboratories is down 26% from its 52-week high due to a soft quarter. With 54 consecutive years of dividend hikes and guidance calling for mid-single-digit organic sales growth plus 10% EPS expansion, the Dividend King seems discounted, but the question is, can it rebound? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.